AUTL - オ―トルス・セラピュ―ティクス （Autolus Therapeutics plc）AUTLのニュース
Wells Fargo Assumes Autolus Therapeutics plc at Overweight 2023/03/27 11:56:06 Investing.com
https://www.investing.com/news/pro/wells-fargo-assumes-autolus-therapeutics-plc-at-overweight-432SI-3040888
Autolus Therapeutics finance chief steps down (NASDAQ:AUTL) 2023/03/14 11:20:23 Seeking Alpha
A clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, Autolus Therapeutics (AUTL) said that Dr. Lucinda Crabtree has provided notice of…
Autolus Therapeutics announces resignation of Chief Financial Officer 2023/03/14 11:00:00 GlobeNewswire
- Dr. Lucinda Crabtree to step down with effect from Q3 2023 –
Autolus Therapeutics plc PT Raised to $2.70 at Goldman Sachs 2023/03/10 11:01:02 Investing.com
https://www.investing.com/news/pro/autolus-therapeutics-plc-pt-raised-to-270-at-goldman-sachs-432SI-3027359
Autolus Therapeutics GAAP EPS of -$1.57 beats by $0.06, revenue of $6.36M misses by $4.47M (NASDAQ:AUTL) 2023/03/07 12:06:30 Seeking Alpha
Autolus Therapeutics press release (NASDAQ:AUTL): FY GAAP EPS of -$1.57 beats by $0.06.Revenue of $6.36M (+173.0% Y/Y) misses by $4.47M.
Autolus'' Blood Cancer CAR T-Cell Therapy Receives Promising Innovative Medicine In UK 2021/08/09 15:57:11 Benzinga
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to Autolus Therapeutics plc''s (NASDAQ: AUTL ) AUTO1 (obecabtagene Full story available on Benzinga.com
Autolus Therapeutics plc 2021 Q2 - Results - Earnings Call Presentation 2021/08/06 16:10:34 Seeking Alpha
Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna 2021/08/02 12:48:57 Benzinga
Autolus Therapeutics plc (NASDAQ: AUTL ) has granted Moderna Inc (NASDAQ: MRNA ) an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus'' proprietary Full story available on Benzinga.com
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer 2021/07/15 11:00:00 Intrado Digital Media
LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Edgar Braendle M.D., Ph.D., as chief development officer. Dr Braendle is joining Autolus executive team today and will lead the company''s development organization.
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021 2021/07/08 11:00:00 Intrado Digital Media
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, August 5, 2021.
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer 2021/07/15 11:00:00 Intrado Digital Media
LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Edgar Braendle M.D., Ph.D., as chief development officer. Dr Braendle is joining Autolus executive team today and will lead the company''s development organization.
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021 2021/07/08 11:00:00 Intrado Digital Media
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, August 5, 2021.
Autolus Therapeutics'' obe-cel shows high clinical activity in blood cancers, shares rise 5% 2021/06/11 11:39:37 Seeking Alpha
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1- Data suggest that long term durability of response in acute lymphoblastic leukemia patients treated with AUTO1 is due to an enrichment of Stem Cell Memory T cells - 2021/05/25 00:00:00 BioSpace
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a publication in Nature Cancer that gives new insight into the mechanism of long-term durability of effect in acute lymphoblastic leukemia patients treated with AUTO1.
Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021 2021/05/21 00:00:00 BioSpace
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, posted notice of its Annual General Meeting to shareholders, which can be viewed and downloaded from www.autolus.com.